Rationale: Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in Southern China. Although combined chemotherapy with radiotherapy has been widely used in treating locally advanced lesions, relapse and metastases remain the primary cause of treatment failure, and are associated with an extremely poor prognosis. Therefore, more efficient and milder therapies are needed.

Patient Concerns: Herein, we report a patient with advanced NPC with intracranial metastases who showed progression during conventional treatment.

Diagnoses: Nonkeratinizing undifferentiated nasopharyngeal carcinoma (stage IV).

Interventions: After the completion of initial chemoradiotherapy and targeted therapy, metastases to brain occurred during follow-up. Ex vivo-cultured allogeneic NK cell infusion was offered.

Outcomes: Although the intracranial metastases did not decrease 10 months after the NK cell treatment, they decreased significantly at 31 months after the treatment and partially disappeared. The tumor response indicated partial response. Furthermore, all of the intracranial metastases continued to decrease at about 42 months after treatment.

Lessons: The brain metastases of NPC are rare with poor prognosis. Radiotherapy in NPC can disrupt the blood-brain barrier, which may contribute to the metastases of brain. This case report will provide rationale for NK cell infusion following regular chemoradiotherapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581140PMC
http://dx.doi.org/10.1097/MD.0000000000022785DOI Listing

Publication Analysis

Top Keywords

nasopharyngeal carcinoma
12
intracranial metastases
12
case report
8
poor prognosis
8
metastases brain
8
cell infusion
8
decrease months
8
metastases
7
chemoradiotherapy combined
4
cell
4

Similar Publications

Longitudinal profiles of oral microbiome in patients with nasopharyngeal carcinoma and their prognostic implications.

J Oral Microbiol

January 2025

State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

Background: Oral microbiome has been associated with various cancers, including nasopharyngeal carcinoma (NPC), but its role in cancer treatment and prognosis remains largely unknown. This study aims to address the dynamic changes in oral microbiome following cancer treatment and their prognostic implications in NPC patients.

Patients And Methods: Unstimulated whole saliva samples were collected from 23 NPC patients before and after treatment, with an average of 2.

View Article and Find Full Text PDF

Consensus on the lung cancer management after third-generation EGFR-TKI resistance.

Lancet Reg Health West Pac

December 2024

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.

Article Synopsis
  • Lung cancer is the most common type of cancer in the Asia-Pacific region, with non-small cell lung cancer (NSCLC) making up about 85% of cases, and a significant mutation rate of 40-60% in Asian patients with lung adenocarcinoma.
  • Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) have improved treatment for NSCLC with mutations, but managing resistance to these drugs is still a major issue with no standardized guidelines.
  • A set of recommendations has been developed, integrating international guidelines and regional clinical experiences, to help healthcare providers classify resistance, conduct clinical testing, and devise treatment strategies for patients struggling with resistance to third-generation EGFR-TKIs.
View Article and Find Full Text PDF

Background: The expression level of Ki-67 in nasopharyngeal carcinoma (NPC) affects the prognosis and treatment options of patients. Our study developed and validated an MRI-based radiomics nomogram for preoperative evaluation of Ki-67 expression levels in nasopharyngeal carcinoma (NPC).

Methods: In all, 133 patients with pathologically-confirmed (post-operatively) NPC who underwent MRI examination in one of two medical centers.

View Article and Find Full Text PDF

SegRap2023: A benchmark of organs-at-risk and gross tumor volume Segmentation for Radiotherapy Planning of Nasopharyngeal Carcinoma.

Med Image Anal

January 2025

School of Mechanical and Electrical Engineering, University of Electronic Science and Technology of China, Chengdu, China; Shanghai Artificial Intelligence Laboratory, Shanghai, China. Electronic address:

Radiation therapy is a primary and effective treatment strategy for NasoPharyngeal Carcinoma (NPC). The precise delineation of Gross Tumor Volumes (GTVs) and Organs-At-Risk (OARs) is crucial in radiation treatment, directly impacting patient prognosis. Despite that deep learning has achieved remarkable performance on various medical image segmentation tasks, its performance on OARs and GTVs of NPC is still limited, and high-quality benchmark datasets on this task are highly desirable for model development and evaluation.

View Article and Find Full Text PDF

circTP63-N suppresses the proliferation and metastasis of nasopharyngeal carcinoma via engaging with HSP90AB1 to modulate the YAP1/Hippo signaling pathway.

Sci China Life Sci

December 2024

NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410078, China.

Circular RNAs (circRNAs) play pivotal roles in the development and progression of various diseases, including malignant tumors. However, the biological functions and the underlying mechanisms of many circRNAs remain elusive. In this study, we identified a novel circRNA, circTP63-N, generated through the splicing of exons 2-4 of the TP63 gene in nasopharyngeal carcinoma (NPC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!